Drugs / IBI3003
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07336472 | Apr 2026 → Dec 2027 expected | plasma cell myeloma | Fortvita Biologics (USA)Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06083207 | Jul 2024 → Oct 2026 expected | plasma cell myeloma | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07623798 | Jun 2026 → May 2029 expected | refractory plasma cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07336472 ↗ |